Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786340 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
A Phase 2 study, sponsored by WinSanTor.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT04786340 is a Phase 2 study that has completed, run by WinSanTor. The registered enrollment target is 58 participants.
The verdict
NCT04786340, a Phase 2 study, has completed, sponsored by WinSanTor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
Interventions
- DRUG Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
- DRUG Placebo: WST-057 4mL topical solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786340
The ClinicalTrials.gov registry entry for NCT04786340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WinSanTor, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution is the first listed.
NCT04786340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04786340 about?
NCT04786340 is a clinical study titled "A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy". This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
What is the current status of trial NCT04786340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2020-11-20. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT04786340?
The interventions under investigation include: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution (DRUG), Placebo: WST-057 4mL topical solution (DRUG).
Who is sponsoring clinical trial NCT04786340?
This trial is sponsored by WinSanTor, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.